Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $15.0B | $0.7B | $4.7B | $3.6B | 4.6% | 31.6% |
| 2025-12-31 | $16.6B | $1.8B | $5.8B | $4.9B | 10.9% | 35.0% |
| 2025-09-30 | $15.8B | $0.2B | $4.6B | $6.6B | 1.2% | 29.1% |
| 2025-06-30 | $15.4B | $0.9B | $5.7B | $4.9B | 6.1% | 37.1% |
| 2025-03-31 | $13.3B | $1.3B | $4.0B | $1.4B | 9.6% | 29.8% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-04-29 | 2.65 | 2.67 | -0.8% |
| 2026-02-04 | 1.02 | 2.87 | -64.5% |
| 2025-10-31 | 1.86 | 1.78 | +4.2% |
| 2025-07-31 | 0.52 | 1.17 | -55.6% |
| 2025-04-25 | 2.46 | 2.40 | +2.6% |
| 2025-01-31 | 2.16 | 2.12 | +1.9% |
| 2024-10-30 | 3.00 | 2.92 | +2.8% |
| 2024-07-25 | 2.65 | 2.66 | -0.4% |
| 2024-04-26 | 2.31 | 2.26 | +2.4% |
| 2024-02-02 | 2.79 | 2.80 | -0.3% |
| 2023-10-27 | 2.95 | 2.87 | +2.8% |
| 2023-07-27 | 2.91 | 2.81 | +3.6% |
| 2023-04-27 | 2.46 | 2.49 | -1.4% |
| 2023-02-09 | 3.60 | 3.58 | +0.7% |
| 2022-10-28 | 3.66 | 3.57 | +2.6% |
| 2022-07-29 | 3.37 | 3.31 | +1.8% |
| 2022-04-29 | 3.16 | 3.14 | +0.6% |
| 2022-02-02 | 3.31 | 3.28 | +0.8% |
| 2021-10-29 | 3.33 | 3.22 | +3.5% |
| 2021-07-30 | 3.11 | 3.03 | +2.6% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $949B | 37.8 | 23.9 | 13.1 | 27.3 | 30.5 | 82.8% | 55.5% | 169.9% | 0.96% |
| UNH | $343B | 28.5 | 18.1 | 0.8 | 18.5 | 3.5 | 18.8% | 2.0% | 0.7% | 5.15% |
| JNJ | $537B | 25.8 | 17.5 | 5.6 | 16.6 | 6.6 | 68.0% | 9.9% | -52.9% | 2.33% |
| MRK | $286B | 32.6 | 12.1 | 4.3 | 11.2 | 6.2 | 76.7% | 4.9% | — | 4.92% |
| ABBV ★ | $381B | 105.6 | 13.3 | 6.1 | 14.8 | -57.2 | 72.0% | 12.4% | -46.2% | 5.47% |
| PFE | $146B | 19.5 | 9.0 | 2.3 | 7.8 | 1.6 | 74.8% | 5.4% | -10.1% | 8.50% |
| TMO | $179B | 26.5 | 17.7 | 4.0 | 19.4 | 3.4 | 40.9% | 6.2% | 11.3% | 3.08% |
| ABT | $151B | 24.4 | 14.3 | 3.4 | 15.2 | 2.9 | 56.5% | 7.8% | -19.7% | 4.19% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 34.79%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 150,698,125 | 8.53% |
| Vanguard Capital Management LLC | 114,880,324 | 6.50% |
| State Street Corporation | 81,217,516 | 4.60% |
| JPMORGAN CHASE & CO | 56,741,691 | 3.21% |
| Vanguard Portfolio Management LLC | 49,523,078 | 2.80% |
| Geode Capital Management, LLC | 46,737,581 | 2.65% |
| Morgan Stanley | 38,016,774 | 2.15% |
| Capital Research Global Investors | 31,254,786 | 1.77% |
| Bank of America Corporation | 23,936,943 | 1.35% |
| FMR, LLC | 21,762,703 | 1.23% |
Insider activity · 90d
No insider trades for ABBV in last 90d.
Analyst estimates
yfinanceConsensus: buy (mean 1.75). Distribution requires FINNHUB_API_KEY.
SEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-05-12 | FORM 8-K | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 10-Q | 2026-05-08 | 10-Q | view · |
| 8-K | 2026-04-29 | 8-K | view · |
| 8-K | 2026-04-03 | 8-K | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| DEF 14A | 2026-03-23 | DEF 14A | view · |
| 4 | 2026-03-06 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-06 | Insider transaction (Form 4) | view · |
| 8-K | 2026-03-04 | FORM 8-K | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-27 | Insider transaction (Form 4) | view · |
| 8-K | 2026-02-26 | FORM 8-K | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 10-K | 2026-02-20 | 10-K | view · |
| 8-K | 2026-02-04 | 8-K | view · |
| 8-K | 2026-01-07 | 8-K | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 10-Q | 2025-11-04 | 10-Q | view · |
| 8-K | 2025-10-31 | 8-K | view · |
| 8-K | 2025-10-03 | 8-K | view · |
| 4 | 2025-10-02 | Insider transaction (Form 4) | view · |
| 4 | 2025-10-02 | Insider transaction (Form 4) | view · |
| 4 | 2025-10-02 | Insider transaction (Form 4) | view · |
| 8-K | 2025-09-11 | FORM 8-K | view · |
| 4 | 2025-08-14 | Insider transaction (Form 4) | view · |
| 4 | 2025-08-07 | Insider transaction (Form 4) | view · |
| 10-Q | 2025-08-04 | 10-Q | view · |
| 8-K | 2025-07-31 | 8-K | view · |
| 8-K | 2025-07-03 | 8-K | view · |
| 4 | 2025-07-02 | Insider transaction (Form 4) | view · |
About
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozur…